EJHaem · 2025
Flow Cytometry Analysis of Mesenchymal Stem Cells: A Predictive Biomarker for Leukemia Transformation in Myelodysplastic Syndrome.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Atance Mireia, Serrano Cristina, Soto Carlos, Alonso-Domínguez Juan Manuel, Blas Carlos, Mata Raquel, Castaño Tamara, Perlado Sara, Arquero Teresa, López-Lorenzo Jose Luis, Pérez M Ángeles, Rosado Belen, Martos Rafael, Rio-Machin Ana, Llamas-Sillero Pilar, Salgado Rocio N, Serrano-López Juana
Аннотация
OBJECTIVE: This study evaluates the prognostic value of bone marrow-derived mesenchymal stem cells (MSCs) in predicting the progression of Myelodysplastic Syndrome (MDS) to Acute Myeloid Leukemia (AML).
METHODS: MSC-like cells were analyzed using flow cytometry in a cohort of 49 MDS patients, including transformed and non-transformed groups.
RESULTS: A non-hematopoietic CD13-bright cell population, enriched for MSC markers CD105 and CD90, was identified in 80% of patients at diagnosis. Elevated of these MSC-like cells were significantly associated with earlier progression to leukemia and reduced overall survival. Multivariate analysis confirmed MSC content as an independent predictor of leukemia transformation.
CONCLUSION: MSC-like cell content at MDS diagnosis may serve as a novel biomarker of predicting malignant transformation to AML. Further validation in larger cohorts and better phenotypic characterization of this cell population are needed.
TRIAL REGISTRATION: The authors have confirmed clinical trial registration is not needed for this submission.
METHODS: MSC-like cells were analyzed using flow cytometry in a cohort of 49 MDS patients, including transformed and non-transformed groups.
RESULTS: A non-hematopoietic CD13-bright cell population, enriched for MSC markers CD105 and CD90, was identified in 80% of patients at diagnosis. Elevated of these MSC-like cells were significantly associated with earlier progression to leukemia and reduced overall survival. Multivariate analysis confirmed MSC content as an independent predictor of leukemia transformation.
CONCLUSION: MSC-like cell content at MDS diagnosis may serve as a novel biomarker of predicting malignant transformation to AML. Further validation in larger cohorts and better phenotypic characterization of this cell population are needed.
TRIAL REGISTRATION: The authors have confirmed clinical trial registration is not needed for this submission.